Geneva–Seattle collaboration in support of developing country vaccine manufacturing

References

• Amarasinghe, A., & Mahoney, R. T. (2011). Estimating potential demand and supply of dengue vaccine in Brazil. Human Vaccines, 7(7), 776–780. doi:10.4161/hv.7.7.16255
   PubMed Web of Science ®Google Scholar
• Armstrong, A. (2014, April 28). GSK-Novartis deal is a game changer for M&A. The Telegraph. Retrieved from http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/10791444/GSK-Novartis-deal-is-a-game-changer-for-MandA.html
   Google Scholar
• Baber, N. (1994). International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). British Journal of Clinical Pharmacology, 37(5), 401–404. doi:10.1111/j.1365-2125.1994.tb05705.x
   PubMed Web of Science ®Google Scholar
• Batson, A., Evans, P., & Milstien, J. B. (1994). The crisis in vaccine supply: A framework for action. Vaccine, 12(11), 963–965. doi:10.1016/0264-410X(94)90328-X
   PubMed Web of Science ®Google Scholar
• Bill and Melinda Gates Foundation. (1999). Bill and Melinda Gates Foundation announces $750 million gift to speed delivery of life-saving vaccines. Retrieved March 2, 2015, from http://www.gatesfoundation.org/Media-Center/Press-Releases/1999/11/Global-Alliance-for-Vaccines-and-Immunization
   Google Scholar
• Birn, A.-E. (2005). Gates's grandest challenge: transcending technology as public health ideology. The Lancet, 366(9484), 514–519.
   Google Scholar
• Birn, A. E. (2014). Philanthrocapitalism, past and present: The Rockefeller Foundation, the Gates Foundation, and the setting (s) of the international/global health agenda. Hypothesis, 12(1), e8. doi:10.5779/hypothesis.v12i1.229
   Google Scholar
• Birn, A. E., & Lexchin, J. (2011). Beyond patents: The GAVI Alliance, AMCs and improving immunization coverage through public sector vaccine production in the global south. Human Vaccines, 7(3), 291–292. doi:10.4161/hv.7.3.15217
   PubMed Web of Science ®Google Scholar
• Bishai, D. M., Champion, C., Steele, M. E., & Thompson, L. (2011). Product development partnerships hit their stride: Lessons from developing a meningitis vaccine for Africa. Health Affairs, 30(6), 1058–1064. doi:10.1377/hlthaff.2011.0295
   Web of Science ®Google Scholar
• Brundtland, G. H. (2002). State of the world’s vaccines and immunizations. JAMA, 288(20), 2532–2532. doi:10.1001/jama.288.20.2532
   PubMed Web of Science ®Google Scholar
• Buse, K., & Walt, G. (2000). Global public-private partnerships: Part I-a new development in health? Bulletin of the World Health Organization, 78(4), 549–561.
   PubMed Web of Science ®Google Scholar
• Chan, M. (2014). Beyond expectations: 40 years of EPI. The Lancet, 383(9930), 1697–1698. doi:10.1016/S0140-6736(14)60751-0
   PubMed Web of Science ®Google Scholar
• Danzon, P. M., & Sousa Pereira, N. (2011). Vaccine supply: Effects of regulation and competition. International Journal of the Economics of Business, 18(2), 239–271. doi:10.3386/w17205
   Google Scholar
• Dellepiane, N., & Wood, D. (2015). Twenty-five years of the WHO vaccines pre qualification programme (1987-2012): Lesson learned and future perspectives. Vaccine, 33, 52–61. doi:10.1016/j.vaccine.2013.11.066
   PubMed Web of Science ®Google Scholar
• DeRoeck, D. (2001). Immunization financing in developing countries and the international vaccine market: Trends and issues. Manila: Asian Development Bank. ISBN: 971-561-349-7
   Google Scholar
• Diagana, M., Preux, P. M., & Dumas, M. (2007). Japanese encephalitis revisited. Journal of the Neurological Sciences, 262(1), 165–170. doi:10.1016/j.jns.2007.06.041
   PubMed Web of Science ®Google Scholar
• Francis, D. P., Du, Y. P., & Precioso, A. R. (2014). Global vaccine supply: The increasing role of manufacturers from middle income countries. Vaccine, 32(41), 5259–5265. doi:10.1016/j.vaccine.2014.07.069
   PubMed Web of Science ®Google Scholar
• Godlee, F. (1994). WHO in crisis. BMJ: British Medical Journal, 309(6966), 1424. doi:10.1136/bmj.309.6966.1424
   Web of Science ®Google Scholar
• Greene, W. (2007). The emergence of India’s pharmaceutical industry and implications for the US generic drug market. Washington, DC: U.S. International Trade Commission.
   Google Scholar
• Halstead, S. B., & Thomas, S. J. (2011). New Japanese encephalitis vaccines: Alternatives to production in mouse brain. Expert Review of Vaccines, 10(3), 355–364. doi:10.1586/erv.11.7
   PubMed Web of Science ®Google Scholar
• Hennessy, S., Strom, B. L., Bilker, W. B., Zhengle, L., Chao-Min, W., Hui-Lian, L., & Halstead, S. B. (1996). Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study. The Lancet, 347(9015), 1583–1586. doi:10.1016/S0140-6736(96)91075-2
   PubMed Web of Science ®Google Scholar
• Hombach, J., Solomon, T., Kurane, I., Jacobson, J., & Wood, D. (2005). Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. Geneva: WHO. 2–3 September, 2004. Vaccine, 23(45), 5205–5211. doi:10.1016/j.vaccine.2005.07.002
   Google Scholar
• International Center for Childhood and the Family. 1998. Vaccines: Financing and management training manual. Paris: International Center for Childhood and the Family.
   Google Scholar
• Kulkarni, K. (2012, July 4). Serum Institute of India buys Dutch vaccine maker for $40.3 mln. Reuters. Retrieved from http://in.reuters.com/article/serum-institute-bilthoven-biologicals-idINDEE8630A220120704
   Google Scholar
• Liu, Z. L., Hennessy, S., Strom, B. L., Tsai, T. F., Wan, C. M., Tang, S. C., & Halstead, S. B. (1997). Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): Results of a randomized trial with 26,239 subjects. The Journal of Infectious Diseases, 176(5), 1366–1369. doi:10.1086/517323
   PubMed Web of Science ®Google Scholar
• Lombard, M., Pastoret, P. P., & Moulin, A. M. (2007). A brief history of vaccines and vaccination. Revue Scientifique et Technique-Office International des Epizooties, 26(1), 29–48. doi: 10.20506/rst.26.1.1724
   PubMed Web of Science ®Google Scholar
• Mahoney, R. T. (2011). Product development partnerships: Case studies of a new mechanism for health technology innovation. Health Research Policy and Systems, 9(1), 101. doi:10.1186/1478-4505-9-33
   Web of Science ®Google Scholar
• Mahoney, R. T., & Maynard, J. E. (1999). The introduction of new vaccines into developing countries. Vaccine, 17(7), 646–652. doi:10.1016/S0264-410X(98)00246-1
   PubMed Web of Science ®Google Scholar
• Mahoney, R. T., Pablos-Mendez, A., & Ramachandran, S. (2004). The introduction of new vaccines into developing countries: III. The role of intellectual property. Vaccine, 22(5), 786–792. doi:10.1016/j.vaccine.2003.04.001
   PubMed Web of Science ®Google Scholar
• Mahoney, R. T., Ramachandran, S., & Xu, Z. Y. (2000). The introduction of new vaccines into developing countries II. Vaccine financing. Vaccine, 18(24), 2625–2635. doi:10.1016/S0264-410X(00)00073-6
   PubMed Web of Science ®Google Scholar
• McCoy, D., Kembhavi, G., Patel, J., & Luintel, A. (2009). The Bill & Melinda Gates Foundation’s grant-making programme for global health. The Lancet, 373(9675), 1645–1653. doi:10.1016/S0140-6736(09)60571-7
   PubMed Web of Science ®Google Scholar
• McCoy, D., & McGoey, L. (2011). Global health and the Gates Foundation–in perspective. In S. Rushton & O. D. Williams (Eds.), Partnerships and foundations in global health governance (pp. 143–163). Basingstoke: Palgrave Macmillan. doi:10.1057/9780230299474_7
   Google Scholar
• McGoey, L. (2014). The philanthropic state: Market–state hybrids in the philanthrocapitalist turn. Third World Quarterly, 35(1), 109–125. doi:10.1080/01436597.2014.868989
   Web of Science ®Google Scholar
• Milstien, J., Batson, A., & Meaney, W. (1997). A systematic method for evaluating the potential viability of local vaccine producers. Vaccine, 15(12), 1358–1363. 1358 doi: 10.1016/S0264-410X(97)00053-4
   PubMed Web of Science ®Google Scholar
• Milstien, J., & Candries, B. (2000). Economics of vaccine development and implementation: Changes over the past 20 years. Geneva: WHO.
   Google Scholar
• Milstien, J., Costa, A., Jadhav, S., & Dhere, R. (2009). Reaching international GMP standards for vaccine production: Challenges for developing countries. Expert Review of Vaccines, 8, 559–566. doi:10.1586/erv.09.23
   PubMed Web of Science ®Google Scholar
• Milstien, J., Glass, S., Batson, A., Greco, M., & Berger, J. (2002). Divergence of vaccine product lines in industrialized and developing countries. Geneva: WHO Department of Vaccines and Biologicals. doi:10.1016/S0264-410X(97)00053-4
   Google Scholar
• Muraskin, W. A. (1995). The war against hepatitis B: A history of the international task force on hepatitis b immunization. Philadelphia: University of Pennsylvania Press.
   Google Scholar
• Offit, P. A. (2005). Why are pharmaceutical companies gradually abandoning vaccines? Health Affairs, 24(3), 622–630. doi:10.1377/hlthaff.24.3.622
   PubMed Web of Science ®Google Scholar
• Ozawa, S., Mirelman, A., Stack, M. L., Walker, D. G., & Levine, O. S. (2012). Cost-effectiveness and economic benefits of vaccines in low-and middle-income countries: A systematic review. Vaccine, 31(1), 96–108. doi:10.1016/j.vaccine.2012.10.103
   PubMed Web of Science ®Google Scholar
• Parmar, I. (2012). Foundations of the American Century: The Ford, carnegie, and rockefeller foundations and the rise of american power. New York: Columbia University Press.
   Google Scholar
• Parry, J. (2014). China enters the global vaccine market. Bulletin of the World Health Organization, 92(9), 626–627. doi:10.2471/BLT.14.020914
   PubMed Web of Science ®Google Scholar
• PATH. (2013). SA 14-14-2 Live Japanese Encephalitis (JE) Vaccine Factsheet. Retrieved August 3, 2016, from https://www.path.org/publications/files/SA14142-fact-sheet-1013.pdf
   Google Scholar
• Ruckert, A., & Labonté, R. (2014). Public–private partnerships (ppps) in global health: The good, the bad and the ugly. Third World Quarterly, 35(9), 1598–1614. doi:10.1080/01436597.2014.970870
   Web of Science ®Google Scholar
• Ruger, J. P., & Yach, D. (2009). The global role of the World Health Organization. Global Health Governance: The Scholarly Journal for the New Health Security Paradigm, 2(2), 1–11.
   PubMedGoogle Scholar
• Sanofi. Biotechnics, S. A. S. (2009). Industry Watch. Asia-Pacific. Biotech News, 13, pp. 29–40.
   Google Scholar
• Shiffman, J. (2006). Donor funding priorities for communicable disease control in the developing world. Health Policy and Planning, 21(6), 411–420. doi:10.1093/heapol/czl028
   PubMed Web of Science ®Google Scholar
• Statens Serum Institut. (2016). Statens Serum Institut sells vaccine production business to AJ Biologics. Retrieved August 8, 2016, from http://www.ssi.dk/English/News/News/2016/2016_06_Vaccineproduction%20sold.aspx
   Google Scholar
• Trouiller, P., Torreele, E., Olliaro, P., White, N., Foster, S., Wirth, D., & Pécoul, B. (2001). Drugs for neglected diseases: A failure of the market and a public health failure? Tropical Medicine and International Health, 6(11), 945–951. doi:10.1046/j.1365-3156.2001.00803.x
   PubMed Web of Science ®Google Scholar
• UNICEF. (2015, July). Japanese Encephalitis Vaccine Market & Supply Update. UNICEF Supply Division. July, 2015. Retrieved April 4, 2016, from http://www.unicef.org/supply/files/JE_Vaccine_Market_and_Supply_Update.pdf
   Google Scholar
• United States Food and Drug Administration. (2013). FDA Provides a Portal to India. Retrieved August 4, 2016, from http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM334338.pdf
   Google Scholar
• United States Food and Drug Administration. (2015). Complete list of vaccines licensed for immunization and distribution in the US. Silver Spring, MD: Consumer Affairs Branch (CBER). Retrieved April 18, 2016, from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm
   Google Scholar
• Watson, M., & Faron de Goër, E. (2016). Are good intentions putting the vaccination ecosystem at risk? Human Vaccines & Immunotherapeutics, 1–6. doi:10.1080/21645515.2016.1172162
   Web of Science ®Google Scholar
• Wheeler, C., and Berkley, S. (2001). Initial lessons from public-private partnerships in drug and vaccine development. Bulletin of the World Health Organization, 79(8), 728–734. doi:10.1590/S0042-96862001000800008
   PubMed Web of Science ®Google Scholar
• Yu, Y. (2010). Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine, 28(21), 3635–3641. doi:10.1016/j.vaccine.2010.02.105
   PubMed Web of Science ®Google Scholar
• Yu, Y. (2013). Development of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and its charcteristics. INTECH Open Access. doi:10.5772/52980
   Google Scholar